Evaluation of the clinical effect of azathioprine lozenge in oral lichen planus
Phase 3
Not yet recruiting
- Conditions
- oral lichen planus.Lichen planus
- Registration Number
- IRCT20191106045356N10
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Women should not be pregnant or breastfeeding
Do not use allopurinol
Do not use viral vaccines during treatment
Patients do not have a confirmed history of allergic reactions following oral administration of azathioprine
The patient does not have a low level of consciousness
The patient should not be treated with warfarin
The patient does not have an active viral disease
Exclusion Criteria
Do not use the drug for two consecutive days
Exacerbation of oral lichen planus lesions
Allergic reaction to azathioprine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Redness and inflammation. Timepoint: At the beginning of treatment and after every 2 to 10 days, the status of oral lichen planus lesions is evaluated for the severity of redness and inflammation (score 0 to 4). Method of measurement: Scoring severe redness and inflammation using a Reeda questionnaire.;Severe pain and burning. Timepoint: At the beginning of treatment and after every 2 to 10 days, the condition of oral lichen planus lesions is evaluated for the severity of pain and burning (score 0 to 4). Method of measurement: Severe pain and burning using VAS questionnaire.
- Secondary Outcome Measures
Name Time Method